HUIYU PHARMACEUTICAL: Injectable Paclitaxel (Albumin-Bound) Obtains Overseas Listing License
HUIYU PHARMACEUTICAL announced that its subsidiary Seacross Pharma (Europe) Ltd. has obtained marketing authorization for injectable paclitaxel (albumin-bound) from the regulatory authorities in the Netherlands, Ireland, Finland, and Sweden. The drug is indicated for the treatment of adult patients with metastatic breast cancer, metastatic pancreatic adenocarcinoma, and non-small cell lung cancer
According to the Zhitong Finance APP, HUIYU PHARMACEUTICAL (688553.SH) announced that its subsidiary Seacross Pharma (Europe) Ltd. recently received marketing authorization for its product, injectable paclitaxel (albumin-bound), from the Dutch Medicines Evaluation Board, the Irish Health Products Regulatory Authority, the Finnish Medicines Agency, and the Swedish Medical Products Agency.
Injectable paclitaxel (albumin-bound) is primarily indicated as a monotherapy for the treatment of adult patients with metastatic breast cancer (those whose condition has not improved after first-line treatment for metastatic disease and for whom standard anthracycline-containing regimens are not suitable); in combination with gemcitabine, it is indicated for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma; and in combination with carboplatin, it is indicated for the initial treatment of adult patients with non-small cell lung cancer who are not suitable for potentially curative surgery and/or radiotherapy
